{"id":"W2246998135","doi":"","title":"AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium.","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Interim analysis; Internal medicine; Phases of clinical research; Renal cell carcinoma; Oncology; Gastroenterology; Neutropenia; Pharmacology; Urology; Surgery; Toxicity; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006621323,0.000437222,0.001019092,0.0002794827,0.0001069936,0.000008735426,0.0003080238,0.0001587772,0.00009034412],"category_scores_gemma":[0.00007730072,0.0003164824,0.0005430108,0.0006906471,0.0002998187,0.00004999703,0.0001482027,0.0004206914,0.000001422228],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004226743,"about_ca_system_score_gemma":0.0005822727,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006830527,"about_ca_topic_score_gemma":0.0002859595,"domain_scores_codex":[0.9965378,0.0002238394,0.001433485,0.0005311837,0.0007786946,0.0004949977],"domain_scores_gemma":[0.9976105,0.0001846166,0.0008370387,0.0009090086,0.0002973291,0.0001614903],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.5749881,0.009970502,0.00002330115,0.0001498576,0.0006365476,0.000280615,0.004981869,0.00003008184,0.392611,0.0000123332,0.00007405263,0.01624179],"study_design_scores_gemma":[0.390038,0.02284778,0.00005909858,0.0001470747,0.001076603,0.00001112146,0.0001807436,0.0001634828,0.5830034,0.00003151739,0.00228156,0.0001596538],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906973,0.002629321,0.000521166,0.001054433,0.0004208745,0.003358879,0.000394671,0.00001716939,0.0009062136],"genre_scores_gemma":[0.9979644,0.0001987169,0.0003158913,0.0007606515,0.0001372144,0.0001230776,0.00004376982,0.00006794143,0.0003883801],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1903924,"threshold_uncertainty_score":0.9999287,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06798462123839182,"score_gpt":0.3577161289842715,"score_spread":0.2897315077458797,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}